Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2020 16:03 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Fourth Quarter and Full Year 2019 Financial Results

- Full year 2019 GOCOVRI® product sales of $54.6 million, a 60% increase over 2018;total paid prescriptions grew approximately 66% to 25,780 - Fourth quarter 2019 GOCOVRI® product sales of $16.3...
February 20, 2020 16:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present at Upcoming Healthcare Conferences

EMERYVILLE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...
February 19, 2020 16:02 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020

EMERYVILLE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday,...
February 13, 2020 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

EMERYVILLE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...
February 11, 2020 16:15 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease

- Final results reported from the longest-running clinical trial of an amantadine product in Parkinson’s disease - Patients taking GOCOVRI experienced long-term reductions in both dyskinesia and OFF...
January 10, 2020 16:30 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new...
January 08, 2020 09:15 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020

-- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 -- -- Total prescriptions of approximately 7,160 for fourth...
January 02, 2020 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Settlement of Patent Litigation with Sandoz Inc.

EMERYVILLE, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...
December 17, 2019 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment

- INROADS study achieved its primary endpoint (proportion of responders with at least a 20% improvement from baseline to Week 12) - - Dose-response observed for both efficacy and safety - - Safety...
December 09, 2019 16:50 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new...